Autopsy report · NCT04312282

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

“The Sponsor has discontinued the development of tesetaxel”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 93 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Odonate Therapeutics, Inc.

Sponsor type

Industry

Conditions

Advanced Solid Tumors

Interventions

Tesetaxel; Tesetaxel; Itraconazole; Rifampin

Participants

93

Sites

3

Countries

United States

Trials that died the same way

• A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
  “The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.” (63% match in meaning)
• Magnetic Muscle Stimulation of Abdominal Muscle
  “Sponsor Discontinued due to business decision.” (60% match in meaning)
• Common Safety Follow-up Trial of Tecemotide (L-BLP25)
  “The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.